ADVANCE: the world’s largest study of treatments for type 2 diabetes
Globally, there are approximately 250 million people with diabetes, most of whom will eventually be killed or disabled by the complications of their condition. The most common cause of death in people with diabetes is heart disease, however kidney disease also affects a large proportion.Against this backdrop, experts at The George Institute led by Professors Stephen MacMahon and John Chalmers, conducted the largest-ever study of treatments designed to prevent these complications of diabetes.
Over six years, researchers studied more than 11,000 patients from 20 countries, in a project focused on two key treatment targets for people with type 2 diabetes – lowering levels of blood pressure and blood glucose.
Initial results showed that more intensive blood pressure lowering reduced the risk of death from cardiovascular diseases, as well as the risks of other complications, with results published in The Lancet.
Subsequent results showed that more intensive blood glucose lowering protected patients against serious kidney complications, with results published in The New England Journal of Medicine.
Results of the ADVANCE study will have implications for the care of most people with diabetes worldwide.
Read more about the ADVANCE study.
